How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 60.5 | 60.5 | 59.1 | 58.1 | 58.1 | 58.1 | -2.4 |
| Healthcare | 30.5 | 30.5 | 31.5 | 33.7 | 33.7 | 33.7 | +3.1 |
| Chemicals | 2.8 | 2.8 | 3.0 | 3.1 | 3.1 | 3.1 | +0.3 |
| Financial Services | 2.6 | 2.6 | 2.5 | 2.5 | 2.5 | 2.5 | -0.1 |
| Digital | 0.7 | 0.7 | 0.6 | 0.5 | 0.5 | 0.5 | -0.1 |
| Unclassified | 0.5 | 0.5 | 0.5 | · | · | · | +0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 11.34% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| DIVISLAB | Pharma | 10.01% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| JBCHEPHARM | Pharma | 6.53% | 9 | 7 | 2 | 5 | 1 | 1/2 | +18.6% |
| ASTERDM | Healthcare | 6.44% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| MANKIND | Pharma | 5.24% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| MAXHEALTH | Healthcare | 4.97% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| AJANTPHARM | Pharma | 4.68% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| KIMS | Healthcare | 4.15% | 7 | 3 | 7 | 4 | 1 | 0/2 | +19.2% |
| LALPATHLAB | Healthcare | 3.27% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| NEULANDLAB | Healthcare | 3.17% | 10 | 10 | 5 | 10 | 2 | 1/2 | +27.4% |
| NAVINFLUOR | Chemicals | 3.10% | 9 | 10 | 3 | 9 | 1 | 0/2 | +21.1% |
| ABBOTINDIA | Pharma | 2.92% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| DRREDDY | Pharma | 2.73% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| TORNTPHARM | Pharma | 2.66% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
| SAILIFE | Healthcare | 2.64% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| ANTHEM | Pharma | 2.19% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| MEDANTA | Healthcare | 1.81% | 9 | 9 | 6 | 8 | 2 | 0/2 | +23.2% |
| CIPLA | Pharma | 1.63% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| FORTIS | Healthcare | 1.47% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| POLICYBZR | Financial Services | 1.37% | 2 | 7 | 2 | 5 | 4 | 0/2 | +0.9% |
| LUPIN | Pharma | 1.35% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| PFIZER | Healthcare | 1.32% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| ICICIGI | Financial Services | 1.15% | 3 | 6 | 5 | 8 | 6 | 0/2 | -2.8% |
| LENSKART | Healthcare | 0.74% | 6 | 1 | 3 | 5 | 1 | 0/2 | -3.6% |
| SAGILITY | Digital | 0.53% | 2 | 9 | 8 | 3 | 9 | 0/2 | -6.5% |
Performance · 1.6y
Over the last 1.6 years ₹100 in the fund grew to ₹115 (+15%), vs ₹98 for Nifty 500 (−2%) and ₹97 for Nifty 50 (−3%). Its relative-strength line ended at 119 vs Nifty 50 and 117 vs Nifty 500 — above 100, sustained outperformance.